FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma

The FDA granted accelerated approval to Tecvayli, Janssen Biotech, Inc., the first bispecific B-cell maturation antigen-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma.